2020 annual financial data
XTL Biopharmaceuticals 2020 Revenue growth
Direct answer
Revenue growth was -59.42%.
Operating income was -948,000 USD and net income was -782,000 USD.
Operating cash flow was -850,000 USD.
Get free XTL Biopharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 28,000 USD
- Operating income
- -948,000 USD
- Net income
- -782,000 USD
- Operating cash flow
- -850,000 USD